Fuhrmann V, Horvatits T, Drolz A, Rutter K
Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland,
Med Klin Intensivmed Notfmed. 2014 May;109(4):246-51. doi: 10.1007/s00063-013-0321-4. Epub 2014 Apr 27.
Acute and acute-on-chronic liver failure are often associated with development of organ failure. Its occurrence is associated with high morbidity and mortality. Extracorporeal replacement therapies are frequently necessary in these patient populations. Replacement therapies can be divided into renal replacement therapies and liver support therapies. These therapies consist of artificial liver support systems (i.e., MARS(®) system, Prometheus(®)), which are able to remove water-soluble and albumin-bound toxins, and of bioartifical liver support systems. This manuscript provides a review of current practice in the extracorporeal support of patients with liver diseases in the intensive care unit.
急性肝衰竭和慢加急性肝衰竭常伴有器官衰竭的发生。其发生与高发病率和高死亡率相关。在这些患者群体中，体外替代治疗常常是必要的。替代治疗可分为肾脏替代治疗和肝脏支持治疗。这些治疗包括人工肝支持系统（即分子吸附再循环系统（MARS®）、普罗米修斯系统（Prometheus®）），它们能够清除水溶性和与白蛋白结合的毒素，以及生物人工肝支持系统。本文综述了重症监护病房中肝病患者体外支持的当前实践。
